News from the Bench

Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.

Subscribe

To Purchase # 2204S

2204S 2.5 mg $69.00
$0.00

Questions?

Find answers on our FAQs page.

ANSWERS  

PhosphoSitePlus® Resource

  • Additional protein information
  • Analytical tools

LEARN MORE

Western blot analysis of extracts from NIH/3T3 cells, untreated (-) or treated (+) with Bortezomib (100 nM, 6 hr), using Ubiquitin Antibody #3933 (left), p53 (1C12) Mouse mAb #2524 (middle), and β-Actin (13E5) Rabbit mAb #4970 (right).

Learn more about how we get our images

Chemical structure of Bortezomib.

Learn more about how we get our images

Western blot analysis of L363 cells, untreated (-) or treated (+) with Bortezomib (24 hr) as indicated, using K48-linkage Specific Polyubiquitin Antibody #4289.

Learn more about how we get our images
Image

Product Usage Information

Bortezomib is supplied as a lyophilized powder. For a 1 mM stock, reconstitute the 2.5 mg in 6.51 ml DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 1-1000 nM for 2-48 hours. Soluble in DMSO and ethanol at 200 mg/ml, very poorly soluble in plain water.


Storage: Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Product Description

Molecular Weight:

384.24 g/mol


Purity:

99%


Molecular Formula:

C19H25BN4O4


Bortezomib (C19H25BN4O4), a boronic acid dipeptide, is a specific, potent, and reversable proteasome inhibitor that has also been shown to have a stabilizing effect on proteins that inhibit cell survival and cell cycle progression, such as p53 (1,2). Researchers have demostrated that bortezomib inhibits activation and nuclear translocation of NF-κB, subsequently decreasing early tumor survival (3). The increase in bortezomib-stablilized, misfolded, and ubiquitinated proteins that interfere with cell survival and other important pathways further support its anti-tumor effects (3).


1.  Williams, S.A. and McConkey, D.J. (2003) Cancer Res 63, 7338-44.

2.  Poulaki, V. et al. (2007) Invest Ophthalmol Vis Sci 48, 4706-19.

3.  Mimnaugh, E.G. et al. (2004) Mol Cancer Ther 3, 551-66.



For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

2204
Bortezomib